Related Experiment Video

Updated: Jun 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Thromboembolism risks in atrial fibrillation]

D Babuty1, L Gorin, N Zannad

  • 1Service de Cardiologie B, Pôle CTVH, Hôpital Trousseau, Université François Rabelais, Tours, France. d.babuty@chu-tours.fr

Annales De Cardiologie Et D'Angeiologie
|January 28, 2010
PubMed

Insights

Atrial fibrillation increases mortality risk, but treatment focuses on preventing thromboembolism events like stroke. Identifying high-risk patients is crucial for effective management and improved outcomes.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Public Health

Context:

  • Atrial fibrillation (AF) is associated with a twofold increase in mortality, excluding cases of lone AF.
  • The primary concern in AF is the elevated risk of thromboembolic events, particularly stroke.
  • Specific conditions like rheumatic mitral valve disease or prosthetic valves significantly heighten this thromboembolic risk.

Purpose:

  • To highlight the critical need for thromboembolism prevention in atrial fibrillation management.
  • To underscore the importance of risk stratification tools like the CHADS2 score.
  • To emphasize the proven efficacy of anticoagulant therapy in reducing AF-related morbidity and mortality.

Summary:

  • Atrial fibrillation (AF) significantly elevates mortality risk, with thromboembolism, especially stroke, being a major complication.
  • The CHADS2 score quantifies annual thromboembolism risk from 1.9% to 18.2%, aiding in patient stratification.
  • Antivitamin K agents have demonstrated effectiveness in reducing mortality and morbidity, necessitating identification of at-risk individuals.

Impact:

  • Establishes the central role of thromboembolism prevention in AF patient care.
  • Reinforces the clinical utility of the CHADS2 score for risk assessment.
  • Supports the continued use of anticoagulation therapy for managing AF-related complications.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...